Immunocore Holdings PLC
IMCR32.630USD
-0.360-1.09%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.64BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immunocore Holdings PLC Unternehmen
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Unternehmensinformationen
BörsenkürzelIMCR
Name des UnternehmensImmunocore Holdings PLC
IPO-datumFeb 05, 2021
CEODr. Bahija Jallal, Ph.D.
Anzahl der mitarbeiter493
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 05
Addresse92 Park Drive Milton Park
StadtABINGDON
BörseNASDAQ Global Select Consolidated
LandUnited Kingdom
PostleitzahlOX14 4RY
Telefon441235438600
Websitehttps://www.immunocore.com/
BörsenkürzelIMCR
IPO-datumFeb 05, 2021
CEODr. Bahija Jallal, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
41.30%
Investment Advisor/Hedge Fund
26.52%
Hedge Fund
22.94%
Corporation
5.15%
Private Equity
3.16%
Research Firm
2.66%
Pension Fund
0.42%
Bank and Trust
0.25%
Venture Capital
0.04%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
292
50.72M
102.46%
-9.05M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
2023Q2
236
43.68M
94.12%
-435.38K
2023Q1
218
40.62M
88.44%
-3.40M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
7.05M
14.25%
+351.61K
+5.25%
Mar 31, 2025
Wellington Management Company, LLP
6.13M
12.39%
-485.33K
-7.33%
Mar 31, 2025
RTW Investments L.P.
4.87M
9.84%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
9.71%
+23.88K
+0.50%
Mar 31, 2025
PRIMECAP Management Company
2.68M
5.41%
+10.10K
+0.38%
Mar 31, 2025
Eli Lilly Vostok SA Geneva
2.55M
5.15%
--
--
Mar 21, 2025
Baker Bros. Advisors LP
2.32M
4.69%
+807.34K
+53.28%
Mar 31, 2025
Tang Capital Management, LLC
1.92M
3.87%
+360.11K
+23.15%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.89M
3.81%
-299.59K
-13.70%
Mar 31, 2025
Kynam Capital Management LP
1.70M
3.43%
+470.00K
+38.35%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Products ETF
1.7%
Tema Oncology ETF
1.18%
ALPS Medical Breakthroughs ETF
1.07%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.1%
iShares Intl Small Cap Equity Factor ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Mehr Anzeigen
Virtus LifeSci Biotech Products ETF
Anteil1.7%
Tema Oncology ETF
Anteil1.18%
ALPS Medical Breakthroughs ETF
Anteil1.07%
Invesco Nasdaq Biotechnology ETF
Anteil0.14%
ProShares Ultra Nasdaq Biotechnology
Anteil0.14%
SPDR S&P International Small Cap ETF
Anteil0.12%
iShares Biotechnology ETF
Anteil0.1%
iShares Intl Small Cap Equity Factor ETF
Anteil0.09%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
SPDR Portfolio Developed World ex-US ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
